|
DPY19L3 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.6286971771251E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
7.81763542789804E-12 |
| Normal-vs-Stage2 |
4.94579999998912E-06 |
| Normal-vs-Stage3 |
3.37759820112637E-11 |
| Normal-vs-Stage4 |
1.35530475731116E-11 |
| Stage1-vs-Stage2 |
6.655400E-01 |
| Stage1-vs-Stage3 |
7.102400E-02 |
| Stage1-vs-Stage4 |
2.121800E-02 |
| Stage2-vs-Stage3 |
1.489580E-01 |
| Stage2-vs-Stage4 |
6.904400E-02 |
| Stage3-vs-Stage4 |
5.588400E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
2.59792187762287E-14 |
| Normal-vs-AfricanAmerican |
1.459070E-03 |
| Normal-vs-Asian |
8.25730039899497E-10 |
| Caucasian-vs-AfricanAmerican |
1.437180E-01 |
| Caucasian-vs-Asian |
5.466800E-01 |
| AfricanAmerican-vs-Asian |
7.724400E-02 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
2.48679965508813E-11 |
| Normal-vs-Female |
1.65500946280872E-12 |
| Male-vs-Female |
6.235400E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
9.71378533165534E-12 |
| Normal-vs-Age(41-60Yrs) |
2.51070275680831E-11 |
| Normal-vs-Age(61-80Yrs) |
9.49063050370569E-12 |
| Normal-vs-Age(81-100Yrs) |
1.341740E-02 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
7.335800E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
3.394000E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
9.437200E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
5.410800E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
8.395600E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
7.746000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
2.36309999999129E-05 |
| Classical-VS-Follicular |
5.164800E-01 |
| Classical-VS-Other |
5.271200E-01 |
| Classical-VS-Normal |
8.58439996864746E-09 |
| Tall-VS-Follicular |
1.238040E-02 |
| Tall-VS-Other |
4.503200E-01 |
| Tall-VS-Normal |
3.49165141244612E-13 |
| Follicular-VS-Other |
7.654200E-01 |
| Follicular-VS-Normal |
2.94959999758149E-08 |
| Other-VS-Normal |
3.739900E-03 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
2.34889885319944E-11 |
| Normal-vs-N1 |
2.50529597067839E-11 |
| N0-vs-N1 |
5.692300E-02 |
|
|
